Page last updated: 2024-11-10

niclofolan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Niclofolan: Proposed fasciolacide. Synonyms: Dertil; Bilevon; Bay 9015. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284586
CHEMBL ID2107116
CHEBI ID135460
SCHEMBL ID1498232
MeSH IDM0014826

Synonyms (47)

Synonym
menichlopholan
5,5'-dichloro-3,3'-dinitrobiphenyl-2,2'-diol
10331-57-4
o,o'-biphenol, 3,3'-dichloro-5,5'-dinitro-
einecs 233-720-0
3,3'-dichloro-5,5'-dinitro-o,o'-biphenol [french]
4,4'-dichloro-6,6'-dinitro-o,o'-biphenol
niclofolan [inn:ban]
niclofolano [inn-spanish]
bilevon m
bayer 9015
4,4'-dichloro-6,6'-dinitro-o,o-biphenol
(1,1'-biphenyl)-2,2'-diol, 5,5'-dichloro-3,3'-dinitro-
brn 2019644
me 3625
niclofolan
niclofolanum [inn-latin]
5,5'-dichloro-2,2'-dihydroxy-3,3'-dinitrobiphenyl
5,5'-dichloro-3,3'-dinitro(1,1'-biphenyl)-2,2'-diol
bay 9015
3,3'-dichloro-5,5'-dinitro-o,o'-biphenol
CHEBI:135460
4-chloro-2-(5-chloro-2-hydroxy-3-nitrophenyl)-6-nitrophenol
niclofolano
unii-82kft81f6w
niclofolanum
82kft81f6w ,
bayer-9015
CHEMBL2107116
c12h6cl2n2o6
AKOS016014052
FT-0630380
XULACPAEUUWKFX-UHFFFAOYSA-N
niclofolan [mart.]
niclofolan [inn]
niclofolan [mi]
SCHEMBL1498232
5,5'-dichloro-3,3'-dinitro-[1,1'-biphenyl]-2,2'-diol
me-3625;bay9015
DTXSID5023249
5,5'-dichloro-3,3'-dinitro-2,2'-biphenyldiol
mfcd00867407
BCP13963
4-chloro-2-(5-chloro-2-hydroxy-3-nitro-phenyl)-6-nitro-phenol
Q27269339
BS-42385
AKOS040744857

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Two dosage regimen, 2 mg and 3 mg per kg body weight repeated after a 72 hour interval was administered to 31 and 4 patients respectively."( Studies on the chemotherapy of human opisthorchiasis: II. Clinical trial of niclofolan.
Bunnag, D; Desakorn, V; Harinasuta, T, 1981
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polychlorobiphenylA biphenyl compound containing between 2 and 10 chlorine atoms attached to the two benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (95.24)18.7374
1990's1 (4.76)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.41 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (13.79%)5.53%
Reviews1 (3.45%)6.00%
Case Studies5 (17.24%)4.05%
Observational0 (0.00%)0.25%
Other19 (65.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]